Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study

Abstract Background Previous case reports have shown the promising antitumor activity of everolimus in solid tumors containing molecular aberrations in PI3K/ATK/mTOR pathway, however, whether it is effective in patients with breast cancer remains unknown. Therefore, we conducted this retrospective c...

Full description

Bibliographic Details
Main Authors: Zhanhong Chen, Yabing Zheng, Wenming Cao, Yuzi Zhang, Zhengyi Zhao, Guoqiang Wang, Jing Zhao, Shangli Cai, Xiying Shao, Jian Huang, Weiwu Ye, Yuan Huang, Wei Li, Xiang Huang, Hao Wu, Xiaojia Wang, Yongmei Yin
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
breast cancer
everolimus
mutation
PI3K/AKT/mTOR
prognosis
Online Access:https://doi.org/10.1002/cam4.2460

Internet

https://doi.org/10.1002/cam4.2460

Similar Items